Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia. 1994

A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
URA CNRS 1172, IBMIG, Poitiers, France.

The capacity of alpha-interferon (alpha-IFN) to induce lymphokine activated killer (LAK) cytotoxicity in the absence of interleukin-2 (IL2) has prompted us to test whether its ability to reduce dramatically the number of Ph1+ clones in chronic myelogenous leukemia (CML) patients is in part mediated through the generation of natural killer (NK) or LAK activity. The latter were tested using NK-sensitive (K562) and NK-resistant (Raji) cell lines in a target-cell colony-growth inhibition assay. Effector cells (E) were patient blood mononuclear cells (MC) without in vitro activation prior to their coculture with targets (T). Here we report that cytogenetic remission in alpha-IFN-treated patients is associated with significantly enhanced NK and LAK activities. Nevertheless, some patients under alpha-IFN therapy were found to develop lymphoid blast crisis despite high levels of NK and LAK activities, and partial or total cytogenetic remission. In contrast, most of the patients who developed nonlymphoid blast crisis presented 100% Ph1+ cells and displayed defective NK and/or LAK activity. These observations could favor the hypothesis that there is an indirect but complex effect of alpha-IFN on leukemic cells, mediated by cells involved in immune surveillance; and also that lymphoid blast cells may actually escape LAK cytotoxicity.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008285 Major Histocompatibility Complex The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement. Histocompatibility Complex,Complex, Histocompatibility,Complex, Major Histocompatibility,Complices, Histocompatibility,Complices, Major Histocompatibility,Histocompatibility Complex, Major,Histocompatibility Complices,Histocompatibility Complices, Major,Major Histocompatibility Complices
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
December 2003, Leukemia & lymphoma,
A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
April 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology,
A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
April 1990, Immunology today,
A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
October 1995, The American journal of medicine,
A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
January 1998, Archivum immunologiae et therapiae experimentalis,
A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
February 1996, Leukemia,
A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
January 1996, Haematologica,
A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
January 1991, Oncology nursing forum,
A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
May 1987, Blood,
A Meseri-Delwail, and V Delwail, and A Brizard, and P Goube de Laforest, and F Guilhot, and J C Lecron
April 1987, Blut,
Copied contents to your clipboard!